SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

CARE reaffirms rating assigned to bank facilities of Cipla

22 Jan 2016 Evaluate

Credit rating agency, Credit Analysis and Research (CARE) has reaffirmed ‘AAA / A1+’ rating to the various bank facilities of Cipla for an aggregate amount of Rs 3,310.50 crore.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.


Cipla Share Price

1458.10 -0.35 (-0.02%)
06-Jul-2026 11:14 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1905.35
Dr. Reddys Labs. 1360.20
Cipla 1458.10
Zydus Lifesciences 1145.00
Lupin 2485.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: